Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2022 07:30 ET | Source: Orgenesis Inc.

Orgenesis reaches next milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madrid

Orgenesis achieves milestone in the placement of the Orgenesis Mobile Processing Units and Lab (OMPUL) for the development of cell and gene therapies at the Hospital OMPULs expected to contribute to...
January 18, 2022 07:30 ET | Source: Orgenesis Inc.

Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing

GERMANTOWN, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
November 29, 2021 07:00 ET | Source: Orgenesis Inc.

Orgenesis and Theracell Joint Venture to Receive up to €32 Million From Greek Government to Accelerate Rollout of POCare Centers and Deployment of OMPULs

JV named a “Priority Investment of Strategic National Importance” by the government of GreeceGranted fast-track licensing and approval status GERMANTOWN, Md., Nov. 29, 2021 (GLOBE NEWSWIRE) --...
November 15, 2021 07:00 ET | Source: Orgenesis Inc.

Orgenesis Announces Collaboration Agreement with Tel Aviv Sourasky Medical Center to Advance Point-of-Care Development and Commercialization of Cell and Gene and Therapies

GERMANTOWN, Md., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
November 04, 2021 07:30 ET | Source: Orgenesis Inc.

Orgenesis Reports 425% Increase in Revenue for the Third Quarter of 2021 Compared to Same Period Last Year

GERMANTOWN, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
November 02, 2021 09:00 ET | Source: Orgenesis Inc.

Orgenesis Schedules Third Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
August 23, 2021 08:00 ET | Source: Orgenesis Inc.

Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform

Goal to accelerate development, QC testing and manufacturing of Orgenesis’ cell and gene therapy platform New assays being developed to potentially enhance the potency of cell and gene therapies for...
August 05, 2021 07:00 ET | Source: Orgenesis Inc.

Orgenesis Second Quarter 2021 Revenue Increases Over Six-Fold to $10.5 Million Compared to Second Quarter 2020 Reflecting Continued Progress of POCare Platform

GERMANTOWN, Md., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
August 03, 2021 08:30 ET | Source: Orgenesis Inc.

Orgenesis Schedules Second Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
July 06, 2021 07:00 ET | Source: Orgenesis Inc.

Orgenesis Achieves Multiple Ranpirnase Development Milestones

FDA Pre-IND consultation completed; submission of phase 2 trial of Ranpirnase for anogenital warts on schedule Licensing partner, Okogen, Inc., presented positive interim phase 2 clinical trial...